Enfermedad de Alzheimer y diabetes mellitus, ¿enfermedad neuroendocrina?
- Zaida R Santana-Rodríguez 1
- Luis G. Hernández-Abad 1
- Ibrahim González Marrero 1
- 1 Universidad de La Laguna (España)
ISSN: 1697-5529
Datum der Publikation: 2022
Nummer: 18
Seiten: 1-7
Art: Artikel
Andere Publikationen in: Majorensis: Revista Electrónica de Ciencia y Tecnología
Zusammenfassung
This paper focuses on studying Alzheimer's disease (AD) as a neuroendocrine disease, as there is evidence to show that people with type 2 (DMT2) or type 1 (DMT1) diabetes have a higher risk of developing AD than people without it. Many researchers, especially the scientist Suzanne La Monte, who called AD "Diabetes Mellitus type 3". This name is due to the fact that patients with AD have characteristics of these two pathologies, especially type 2 diabetes. So, it has also been shown that drugs used for the treatment of this disease are yielding beneficial results for AD.